Lyell Immunopharma annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma R&D Spending Growth & History (LYEL)
Lyell Immunopharma's r&d spending was $158.7M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $158.7M | −$12.9M | −7.53% |
| 2024 | 2024-12-31 | $171.6M | −$11.3M | −6.20% |
| 2023 | 2023-12-31 | $182.9M | $23.8M | +14.92% |
| 2022 | 2022-12-31 | $159.2M | $20.5M | +14.78% |
| 2021 | 2021-12-31 | $138.7M | −$43.5M | −23.90% |
| 2020 | 2020-12-31 | $182.2M | $118.6M | +186.57% |
| 2019 | 2019-12-31 | $63.6M | — | — |
Lyell Immunopharma quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $39.5M | $4.7M | +13.39% |
| Q1 2026 | 2026-03-31 | $36.6M | −$6.8M | −15.75% |
| Q4 2025 | 2025-12-31 | $52.2M | $3.5M | +7.26% |
| Q3 2025 | 2025-09-30 | $28.2M | −$11.3M | −28.68% |
| Q2 2025 | 2025-06-30 | $34.9M | −$5.4M | −13.42% |
| Q1 2025 | 2025-03-31 | $43.4M | $273,000 | +0.63% |
| Q4 2024 | 2024-12-31 | $48.7M | $1.7M | +3.56% |
| Q3 2024 | 2024-09-30 | $39.5M | −$4.3M | −9.92% |
| Q2 2024 | 2024-06-30 | $40.3M | −$7.2M | −15.19% |
| Q1 2024 | 2024-03-31 | $43.2M | −$1.5M | −3.26% |
| Q4 2023 | 2023-12-31 | $47.0M | $9.0M | +23.57% |
| Q3 2023 | 2023-09-30 | $43.8M | $2.2M | +5.39% |
| Q2 2023 | 2023-06-30 | $47.5M | $3.8M | +8.58% |
| Q1 2023 | 2023-03-31 | $44.6M | $8.8M | +24.56% |
| Q4 2022 | 2022-12-31 | $38.0M | $18.7M | +97.21% |
| Q3 2022 | 2022-09-30 | $41.6M | $10.2M | +32.37% |
| Q2 2022 | 2022-06-30 | $43.7M | −$2.7M | −5.87% |
| Q1 2022 | 2022-03-31 | $35.8M | −$5.7M | −13.72% |
| Q4 2021 | 2021-12-31 | $19.3M | — | — |
| Q3 2021 | 2021-09-30 | $31.4M | $6.9M | +28.29% |
| Q2 2021 | 2021-06-30 | $46.4M | −$50.7M | −52.19% |
| Q1 2021 | 2021-03-31 | $41.5M | — | — |
| Q3 2020 | 2020-09-30 | $24.5M | — | — |
| Q2 2020 | 2020-06-30 | $97.2M | — | — |
Lyell Immunopharma r&d spending trends
Over the last five fiscal years, Lyell Immunopharma's r&d spending decreased from $182.2M to $158.7M, a change of −$23.6M. The latest reported quarter, Q2 2026, shows $39.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗